Updates in the Treatment of HER2+ and HER2-Low Breast Cancer

Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.

EP. 1: Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

EP. 2: HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

EP. 3: Subcutaneous HP Therapy in Early-Stage HER2+ Breast Cancer

July 4th 2022

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

EP. 4: Early Stage HER2+ Breast Cancer: Optimizing Use of T-DM1

July 4th 2022

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

EP. 5: Establishing the Role of Neratinib Therapy in Early-Stage HER2+ Breast Cancer

July 11th 2022

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

EP. 6: Early-Stage HER2+ Breast Cancer: Novel Perioperative Treatment Strategies

July 11th 2022

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

EP. 7: Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

EP. 8: Overview of Treatment Options in HER2+ Metastatic Breast Cancer

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

EP. 9: HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

EP. 10: Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

EP. 11: HER2+ mBC: Practical Selection and Sequencing of Therapy

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

EP. 12: Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

EP. 13: Establishing the Paradigm of HER2-Low Breast Cancer

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

EP. 14: Novel Treatment Strategies for HER2-Low Breast Cancer

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

EP. 15: Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

EP. 16: Future Directions in Care for HER2+ Breast Cancer

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.